Ibrutinib improved event-free survival, but its effect on overall survival is unclear.
The median PFS was 10.6 months in the nivolumab group and 10.3 months in the placebo group.
The approval of Fyarro was based on data from the phase 2 AMPECT study.
Upper-limb disability at 1 year decreased with exercise.
Between 2015 and 2019, Black and Hispanic patients were underrepresented in trials of colorectal, lung, and prostate cancer.
If ICU bed use reached 75% capacity nationwide, an excess of 12,000 deaths would be expected 2 weeks later.
Patient satisfaction scores before the pandemic were comparable to scores during the pandemic.
A study of patients with localized prostate cancer showed that 13% reported treatment-related regret.
NBTXR3 plus radiotherapy did not negatively affect quality of life or long-term morbidity in locally advanced soft tissue sarcoma.
Researchers sought to determine the effect of CEBPA-bZip mutations on disease prognosis for patients with acute myeloid leukemia.
At 60 days, there were 2.5 fewer deaths per 1000 patients in the remote monitoring group.
About 84% of COVID-19 hospitalizations were among unvaccinated patients.
STK11 and KEAP1 mutations were independent predictors of shorter progression-free and overall survival in KRAS-mutant cases.
Any adult who received a second dose of either vaccine at least 6 months earlier should be able to get a booster shot.
Researchers found that lack of radiosensitivity was associated with poor outcomes in patients with myxoid liposarcomas.